Sanofi's Breast Cancer Drug Fallout 'Creates Buying Opportunity' For This Stock

  • According to Oppenheimer analyst, the fallout of Sanofi SA's SNY amcenestrant creates a buying opportunity for Arvinas Inc ARVN 
  • The analyst notes that Arvinas shares were pressured after Sanofi decided to discontinue the development of amcenestrant. 
  • Related: Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial.
  • The analyst reiterated an Outperform rating and $102 price target on Arvinas shares, notes that Arvinas ARV-471 is clinically and mechanistically differentiated from competitors in the oral SERD landscape and that it has shown promising single-agent activity in a challenging Phase 1 study population. 
  • The analyst writes, "upcoming VERITAC data focusing on 200 and 500 mg doses, likely to be presented in December, could position '471 as a viable orally-available alternative to fulvestrant."
  • ARV-471 is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the estrogen receptor for locally advanced or metastatic ER+/HER2- breast cancer.
  • Price Action: ARVN shares closed 11% lower at $46.70 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetReiterationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!